These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38696053)

  • 1. Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
    Tsuchihashi K; Ito M; Okumura Y; Nio K; Ozaki Y; Nishio H; Ichihara E; Miura Y; Endo M; Yano S; Maruyama D; Yoshinami T; Susumu N; Takekuma M; Motohashi T; Ochi N; Kubo T; Uchino K; Kimura T; Kamiyama Y; Nakao S; Tamura S; Nishimoto H; Kato Y; Sato A; Takano T; Baba E
    Int J Clin Oncol; 2024 Jun; 29(6):700-705. PubMed ID: 38696053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colony-stimulating factors for chemotherapy-induced febrile neutropenia.
    Mhaskar R; Clark OA; Lyman G; Engel Ayer Botrel T; Morganti Paladini L; Djulbegovic B
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD003039. PubMed ID: 25356786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
    Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia.
    Cornes P; Gascon P; Chan S; Hameed K; Mitchell CR; Field P; Latymer M; Arantes LH
    Adv Ther; 2018 Nov; 35(11):1816-1829. PubMed ID: 30298233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
    Ito M; Okumura Y; Nio K; Baba E; Ozaki Y; Nishio H; Ichihara E; Miura Y; Endo M; Yano S; Maruyama D; Yoshinami T; Susumu N; Takekuma M; Motohashi T; Ochi N; Kubo T; Uchino K; Kimura T; Kamiyama Y; Nakao S; Tamura S; Nishimoto H; Kato Y; Sato A; Takano T; Tsuchihashi K
    Int J Clin Oncol; 2024 Jun; 29(6):689-699. PubMed ID: 38578596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology.
    Hirose T; Ito M; Tsuchihashi K; Ozaki Y; Nishio H; Ichihara E; Miura Y; Yano S; Maruyama D; Yoshinami T; Susumu N; Takekuma M; Motohashi T; Baba E; Ochi N; Kubo T; Uchino K; Kimura T; Kamiyama Y; Nakao S; Tamura S; Nishimoto H; Kato Y; Sato A; Takano T; Endo M
    Int J Clin Oncol; 2024 Aug; 29(8):1081-1087. PubMed ID: 38904887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
    Bohlius J; Herbst C; Reiser M; Schwarzer G; Engert A
    Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD003189. PubMed ID: 18843642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022.
    Nozawa K; Ozaki Y; Yoshinami T; Yokoe T; Nishio H; Tsuchihashi K; Ichihara E; Miura Y; Endo M; Yano S; Maruyama D; Susumu N; Takekuma M; Motohashi T; Ito M; Baba E; Ochi N; Kubo T; Uchino K; Kimura T; Kamiyama Y; Nakao S; Tamura S; Nishimoto H; Kato Y; Sato A; Takano T
    Int J Clin Oncol; 2024 Aug; 29(8):1074-1080. PubMed ID: 38900215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
    Bohlius J; Reiser M; Schwarzer G; Engert A
    Cochrane Database Syst Rev; 2004; (3):CD003189. PubMed ID: 15266474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement.
    Adamo V; Antonuzzo L; Danova M; De Laurentiis M; Marchetti P; Pinto C; Rosti G
    Support Care Cancer; 2022 Dec; 30(12):9877-9888. PubMed ID: 36334157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy.
    Herbst C; Naumann F; Kruse EB; Monsef I; Bohlius J; Schulz H; Engert A
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007107. PubMed ID: 19160320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colony stimulating factors for chemotherapy induced febrile neutropenia.
    Clark OA; Lyman G; Castro AA; Clark LG; Djulbegovic B
    Cochrane Database Syst Rev; 2003; (3):CD003039. PubMed ID: 12917942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
    Kawahira M; Yokota T; Hamauchi S; Kawai S; Yoshida Y; Onozawa Y; Tsushima T; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
    Int J Clin Oncol; 2018 Dec; 23(6):1189-1195. PubMed ID: 29948238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of chemotherapy-induced febrile neutropenia and use of granulocyte colony-stimulating factor in patients with soft tissue or bone sarcoma.
    Mazzaro RT; Vaz MV; Badin RC; Bernardina ED; Manaças LRA
    J Oncol Pharm Pract; 2023 Sep; 29(6):1428-1436. PubMed ID: 36226408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
    Yoshinami T; Nozawa K; Yokoe T; Ozaki Y; Nishio H; Tsuchihashi K; Ichihara E; Miura Y; Endo M; Yano S; Maruyama D; Susumu N; Takekuma M; Motohashi T; Ito M; Baba E; Ochi N; Kubo T; Uchino K; Kimura T; Kamiyama Y; Nakao S; Tamura S; Nishimoto H; Kato Y; Sato A; Takano T
    Int J Clin Oncol; 2024 Jun; 29(6):681-688. PubMed ID: 38649648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology.
    Hirose T; Ito M; Tsuchihashi K; Ozaki Y; Nishio H; Ichihara E; Miura Y; Yano S; Maruyama D; Yoshinami T; Susumu N; Takekuma M; Motohashi T; Baba E; Ochi N; Kubo T; Uchino K; Kimura T; Kamiyama Y; Nakao S; Tamura S; Nishimoto H; Kato Y; Sato A; Takano T; Endo M
    Int J Clin Oncol; 2024 Aug; 29(8):1067-1073. PubMed ID: 38865026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer.
    Repetto L; Biganzoli L; Koehne CH; Luebbe AS; Soubeyran P; Tjan-Heijnen VC; Aapro MS
    Eur J Cancer; 2003 Nov; 39(16):2264-72. PubMed ID: 14556916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.